Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 0.7x - 0.7x | 0.7x |
| Selected Fwd Ps Multiple | 0.5x - 0.6x | 0.6x |
| Fair Value | ₩5,943 - ₩6,569 | ₩6,256 |
| Upside | 18.2% - 30.6% | 24.4% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| MYUNGMOON Pharm co.,Ltd | - | KOSE:A017180 |
| Daehan Nupharm Co.,Ltd. | - | KOSDAQ:A054670 |
| Korea Arlico Pharm Co.,Ltd. | - | KOSDAQ:A260660 |
| RP Bio Inc. | - | KOSDAQ:A314140 |
| Daihan Pharmaceutical Co.,Ltd. | - | KOSDAQ:A023910 |
| DongKoo Bio & Pharma Co., Ltd. | - | KOSDAQ:A006620 |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| A017180 | A054670 | A260660 | A314140 | A023910 | A006620 | |||
| KOSE:A017180 | KOSDAQ:A054670 | KOSDAQ:A260660 | KOSDAQ:A314140 | KOSDAQ:A023910 | KOSDAQ:A006620 | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 4.5% | 8.6% | 10.5% | 12.2% | 3.9% | NM- | ||
| 3Y CAGR | 10.6% | 6.7% | 10.8% | 2.5% | 6.0% | 17.1% | ||
| Latest Twelve Months | 8.2% | -0.3% | 6.8% | -15.2% | 3.1% | 5.3% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -4.9% | 5.9% | 3.0% | 2.3% | 13.7% | 4.4% | ||
| Prior Fiscal Year | -2.7% | 6.1% | 1.6% | 3.6% | 14.5% | 5.5% | ||
| Latest Fiscal Year | -1.6% | 7.7% | -2.8% | -0.7% | 16.5% | 0.8% | ||
| Latest Twelve Months | 0.6% | 5.1% | -1.6% | 1.0% | 16.2% | -1.2% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 12.0x | 7.3x | 23.2x | 7.6x | 0.9x | 7.7x | ||
| Price / LTM Sales | 0.3x | 0.5x | 0.4x | 0.4x | 0.8x | 0.6x | ||
| LTM P/E Ratio | 48.2x | 9.7x | -22.4x | 41.2x | 5.2x | -44.7x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.3x | 0.4x | 0.8x | |||||
| Historical LTM P/S Ratio | 0.5x | 0.8x | 1.6x | |||||
| Selected Price / Sales Multiple | 0.7x | 0.7x | 0.7x | |||||
| (x) LTM Sales | 243,743 | 243,743 | 243,743 | |||||
| (=) Equity Value | 158,743 | 167,098 | 175,453 | |||||
| (/) Shares Outstanding | 27.0 | 27.0 | 27.0 | |||||
| Implied Value Range | 5,870.21 | 6,179.17 | 6,488.13 | |||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 5,870.21 | 6,179.17 | 6,488.13 | 5,030.00 | ||||
| Upside / (Downside) | 16.7% | 22.8% | 29.0% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | A017180 | A054670 | A260660 | A314140 | A023910 | A006620 | |
| Value of Common Equity | 58,600 | 98,808 | 69,201 | 53,905 | 173,166 | 136,022 | |
| (/) Shares Outstanding | 33.4 | 14.0 | 15.3 | 8.7 | 5.9 | 27.0 | |
| Implied Stock Price | 1,753.00 | 7,040.00 | 4,515.00 | 6,220.00 | 29,450.00 | 5,030.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1,753.00 | 7,040.00 | 4,515.00 | 6,220.00 | 29,450.00 | 5,030.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |